Published in Nat Genet on September 25, 2008
Influence of Adiponutrin in Chronic Liver Disease | NCT01122797
A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men | NCT04186260
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 6.85
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Clan genomics and the complex architecture of human disease. Cell (2011) 4.53
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet (2009) 3.24
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest (2011) 3.12
FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling. Cell Metab (2012) 2.96
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res (2009) 2.75
A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet (2009) 2.68
Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A (2012) 2.62
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2014) 2.49
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 2.48
On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women's Genome Health Study. PLoS Genet (2010) 2.48
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology (2010) 2.35
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int (2014) 2.21
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol (2013) 1.98
Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res (2008) 1.95
NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol (2013) 1.90
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet (2014) 1.86
Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology (2014) 1.81
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology (2011) 1.79
Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol (2013) 1.77
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res (2010) 1.75
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab (2012) 1.71
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology (2010) 1.71
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun (2014) 1.66
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet (2015) 1.62
Adipocyte metabolism and obesity. J Lipid Res (2008) 1.62
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One (2012) 1.56
The genetics of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.55
PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. Nat Genet (2012) 1.55
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem (2011) 1.53
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
Genetic determinants of hepatic steatosis in man. J Lipid Res (2011) 1.52
Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci (2011) 1.50
Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev (2013) 1.49
Nonalcoholic fatty liver disease. J Lipid Res (2008) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest (2012) 1.45
Retracted Coordinated regulation of hepatic energy stores by leptin and hypothalamic agouti-related protein. J Neurosci (2013) 1.44
Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr (2010) 1.43
Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science (2014) 1.42
Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol (2011) 1.41
Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry (2010) 1.41
The metabolically benign and malignant fatty liver. Diabetes (2011) 1.39
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest (2016) 1.37
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest (2017) 1.36
Toward a unifying hypothesis of metabolic syndrome. Pediatrics (2012) 1.36
Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35
Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol (2011) 1.30
Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol (2010) 1.29
Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol (2014) 1.29
Dissociating fatty liver and diabetes. Trends Endocrinol Metab (2012) 1.29
Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling. Chem Rev (2011) 1.28
Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int (2011) 1.27
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci (2013) 1.25
Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet (2013) 1.24
The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol (2014) 1.23
The role of hepatokines in metabolism. Nat Rev Endocrinol (2013) 1.21
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology (2011) 1.21
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology (2010) 1.20
Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet (2010) 1.20
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet (2014) 1.20
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 1.20
Lipids and HCV. Semin Immunopathol (2012) 1.19
Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One (2012) 1.19
The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One (2011) 1.18
PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol (2013) 1.18
Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered (2013) 1.17
Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes (2010) 1.17
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology (2013) 1.16
The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr (2010) 1.15
Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics (2003) 53.11
Whole-genome patterns of common DNA variation in three human populations. Science (2005) 21.22
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol (2004) 9.43
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
Admixture mapping for hypertension loci with genome-scan markers. Nat Genet (2005) 6.78
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem (2004) 5.80
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab (2007) 4.51
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis (2004) 3.06
Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol (2008) 3.03
Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging (1995) 2.77
Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res (2005) 2.56
The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad. Biochemistry (2003) 2.51
Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem (2001) 2.33
Characterization of the human patatin-like phospholipase family. J Lipid Res (2006) 2.21
Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol (2004) 2.17
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci U S A (2008) 1.89
Is NASH underdiagnosed among African Americans? Am J Gastroenterol (2002) 1.79
Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb (1993) 1.65
Inhibition of Diabrotica Larval Growth by Patatin, the Lipid Acyl Hydrolase from Potato Tubers. Plant Physiol (1995) 1.49
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature (2009) 18.38
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Replicating genotype-phenotype associations. Nature (2007) 16.11
RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol (2013) 15.51
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet (2007) 10.92
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol (2004) 9.43
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A (2006) 8.20
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
The amphioxus genome and the evolution of the chordate karyotype. Nature (2008) 8.03
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet (2008) 7.31
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
VISTA Enhancer Browser--a database of tissue-specific human enhancers. Nucleic Acids Res (2006) 7.04
dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat (2011) 6.97
Metagenomic discovery of biomass-degrading genes and genomes from cow rumen. Science (2011) 6.93
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature (2003) 6.40
Genomic views of distant-acting enhancers. Nature (2009) 6.27
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat (2013) 5.11
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Deletion of ultraconserved elements yields viable mice. PLoS Biol (2007) 4.81
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
Generalized T2 test for genome association studies. Am J Hum Genet (2002) 4.55
Clan genomics and the complex architecture of human disease. Cell (2011) 4.53
Massively parallel functional dissection of mammalian enhancers in vivo. Nat Biotechnol (2012) 4.51
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Deep resequencing reveals excess rare recent variants consistent with explosive population growth. Nat Commun (2010) 4.39
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
ChIP-Seq identification of weakly conserved heart enhancers. Nat Genet (2010) 4.32
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet (2008) 4.04
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Close sequence comparisons are sufficient to identify human cis-regulatory elements. Genome Res (2006) 3.92